Paul W H I Parren

List of Publications by Year in Descending Order

198 papers	18,636 citations	77 h-index	134 g-index
224 ext. papers	21,047 ext. citations	10.3 avg, IF	6.26 L-index

#	Paper	IF	Citations
198	Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells.. *Journal of Oncology*, **2022**, 2022, 3577928	4.5	0
197	Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5
196	C1q binding to surface-bound IgG is stabilized by C1rs proteases. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	6
195	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vδ1Vγ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies. *Cancer Immunology Research*, **2021**, 9, 50-61	12.5	5
194	A Bispecific Single-Domain Antibody Boosts Autologous Vδ1Vγ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2021**, 27, 1744-1755	12.9	4
193	Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. *Journal of Biological Chemistry*, **2021**, 296, 100641	5.4	23
192	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. *EBioMedicine*, **2020**, 52, 102625	8.8	28
191	DuoHexaBody-CD37, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. *Blood Cancer Journal*, **2020**, 10, 30	7	12
190	Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen Recognition. *ACS Nano*, **2020**, 14, 2739-2750	16.7	16
189	Templated insertions at VD and DJ junctions create unique B-cell receptors in the healthy B-cell repertoire. *European Journal of Immunology*, **2020**, 50, 2099-2101	6.1	2
188	Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. *Molecular Cancer Therapeutics*, **2020**, 19, 2126-2138	6.1	8
187	Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces. *Nano Letters*, **2019**, 19, 4787-4796	11.5	35
186	Bispecific antibodies: a mechanistic review of the pipeline. *Nature Reviews Drug Discovery*, **2019**, 18, 585-608	64.8	395
185	CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. *Haematologica*, **2019**, 104, 1841-1852	6.6	26
184	Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies. *Hla*, **2019**, 94, 415-424	1.9	4
183	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. *JCI Insight*, **2019**, 4,	9.9	27
182	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. *British Journal of Haematology*, **2019**, 184, 475-479	4.5	14

181	Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab **2018**, 153-195		1
180	Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells". *Journal of Immunology*, **2018**, 200, 2517	5.3	
179	Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. *Science*, **2018**, 359, 794-797	33.3	78
178	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. *Nature Medicine*, **2018**, 24, 203-212	50.5	118
177	Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies. *Blood*, **2018**, 132, 1664-1664	2.2	3
176	Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models. *Blood*, **2018**, 132, 4170-4170	2.2	
175	Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells. *Journal of Immunology*, **2017**, 198, 1585-1594	5.3	13
174	Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more. *MAbs*, **2017**, 9, 898-906	6.6	25
173	Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. *Clinical Immunology*, **2017**, 181, 24-28	9	10
172	Enhancing Accuracy in Molecular Weight Determination of Highly Heterogeneously Glycosylated Proteins by Native Tandem Mass Spectrometry. *Analytical Chemistry*, **2017**, 89, 4793-4797	7.8	22
171	Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange. *Analytical Chemistry*, **2017**, 89, 10873-10882	7.8	8
170	Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys. *Scientific Reports*, **2017**, 7, 992	4.9	6
169	Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models. *Scientific Reports*, **2017**, 7, 2476	4.9	26
168	A novel label-free cell-based assay technology using biolayer interferometry. *Biosensors and Bioelectronics*, **2017**, 87, 388-395	11.8	23
167	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2017**, 23, 1493-1505	12.9	28
166	Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63. *Molecular Cancer Therapeutics*, **2016**, 15, 2688-2697	6.1	53
165	ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. *Molecular Cancer Therapeutics*, **2016**, 15, 2709-2721	6.1	73
164	Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. *Journal of Immunology*, **2016**, 197, 4829-4837	5.3	23

163	Hitting Ebola, to the power of two. *Science*, **2016**, 354, 284-285	33.3	3
162	A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. *Cancer Research*, **2016**, 76, 3942-53	10.1	107
161	The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc Receptor-Mediated Cross-Linking. *Journal of Immunology*, **2016**, 197, 807-13	5.3	169
160	Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen. *Molecular Cell*, **2016**, 63, 135-45	17.6	91
159	Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. *Molecular Immunology*, **2016**, 70, 13-23	4.3	22
158	The INNs and outs of antibody nonproprietary names. *MAbs*, **2016**, 8, 1-9	6.6	38
157	Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. *OncoImmunology*, **2016**, 5, e1058459	7.2	18
156	High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe. *Journal of Biomolecular Screening*, **2016**, 21, 12-23		26
155	A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. *PLoS Biology*, **2016**, 14, e1002344	9.7	100
154	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. *Haematologica*, **2016**, 101, 616-25	6.6	100
153	Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. *Aids*, **2016**, 30, 1543-51	3.5	40
152	Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. *Journal of Immunology*, **2016**, 197, 1762-75	5.3	40
151	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. *Immunological Reviews*, **2016**, 270, 95-112	11.3	197
150	Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. *MAbs*, **2015**, 7, 672-80	6.6	43
149	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. *Clinical Cancer Research*, **2015**, 21, 2802-10	12.9	107
148	When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. *Transfusion*, **2015**, 55, 1555-62	2.9	101
147	Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion Da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector. *Analytical Chemistry*, **2015**, 87, 6095-102	7.8	70
146	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. *MAbs*, **2015**, 7, 311-21	6.6	315

145	High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. *Molecular Cancer Therapeutics*, **2015**, 14, 1130-40	6.1	41
144	Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics. *Molecular Immunology*, **2015**, 67, 117-30	4.3	88
143	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. *Haematologica*, **2015**, 100, 263-8	6.6	82
142	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. *Haematologica*, **2015**, 100, 77-86	6.6	115
141	Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.. *Journal of Clinical Oncology*, **2015**, 33, 3066-3066	2.2	4
140	Complement is activated by IgG hexamers assembled at the cell surface. *Science*, **2014**, 343, 1260-3	33.3	424
139	Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer **2014**, 239-255		5
138	Controlled Fab-arm exchange for the generation of stable bispecific IgG1. *Nature Protocols*, **2014**, 9, 2450-63	8.8	68
137	Ofatumumab (Arzerra): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity **2014**, 1733-1774		
136	An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. *Cancer Research*, **2014**, 74, 1214-26	10.1	103
135	Opening the door to innovation. *MAbs*, **2014**, 6, 812-9	6.6	12
134	HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. *MAbs*, **2014**, 6, 392-402	6.6	17
133	Mind the gap. *Methods*, **2014**, 65, 1-4	4.6	1
132	Abstract DDT01-03: Discovery and preclinical pharmacology of JNJ-61186372: A novel bispecific antibody targeting EGFR and cMET **2014**,		2
131	Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79. *Blood*, **2014**, 124, 3474-3474	2.2	111
130	Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions. *Blood*, **2014**, 124, 4680-4680	2.2	5
129	CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma. *Blood*, **2014**, 124, 4759-4759	2.2	8
128	Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30. *Blood*, **2014**, 124, 1779-1779	2.2	

127	A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab. *Journal of Immunological Methods*, **2013**, 388, 8-17	2.5	9
126	Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. *Molecular Immunology*, **2013**, 53, 35-42	4.3	29
125	Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. *MAbs*, **2013**, 5, 962-73	6.6	40
124	Antibody Engineering and Therapeutics Conference. *MAbs*, **2013**, 5, 817-825	6.6	1
123	Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 5145-50	11.5	202
122	IgA EGFR antibodies mediate tumour killing in vivo. *EMBO Molecular Medicine*, **2013**, 5, 1213-26	12	81
121	Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. *MAbs*, **2013**, 5, 219-28	6.6	54
120	In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. *MAbs*, **2013**, 5, 917-24	6.6	67
119	CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients. *Blood*, **2013**, 122, 277-277	2.2	3
118	Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma. *Blood*, **2013**, 122, 375-375	2.2	1
117	Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL. *Blood*, **2013**, 122, 378-378	2.2	5
116	Use of an antibody-drug conjugate targeting tissue factor to induce complete tumor regression in xenograft models with heterogeneous target expression.. *Journal of Clinical Oncology*, **2013**, 31, 3066-3066	2.2	1
115	Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. *Journal of Immunology*, **2012**, 188, 3532-41	5.3	90
114	Oncogenic KRAS impairs EGFR antibodiesPefficiency by C/EBPEdependent suppression of EGFR expression. *Neoplasia*, **2012**, 14, 190-205	6.4	15
113	Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. *Blood*, **2012**, 120, e9-e16	2.2	92
112	Online nanoliquid chromatography-mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis. *Analytical Biochemistry*, **2012**, 423, 153-62	3.1	28
111	Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 5548	11.5	3
110	Fab-arm exchange: whatB in a name?. *MAbs*, **2012**, 4, 636	6.6	3

109	Crosstalk between human IgG isotypes and murine effector cells. *Journal of Immunology*, **2012**, 189, 3430-8	5.3	147
108	Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. *Journal of Immunology*, **2012**, 189, 5037-46	5.3	41
107	A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. *Journal of Virology*, **2012**, 86, 6189-96	6.6	96
106	Antibody C region influences TGN1412-like functional activity in vitro. *Journal of Immunology*, **2012**, 189, 5831-40	5.3	16
105	Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor. *PLoS ONE*, **2012**, 7, e39706	3.7	21
104	A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein. *PLoS ONE*, **2011**, 6, e20927	3.7	14
103	The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. *Haematologica*, **2011**, 96, 1822-30	6.6	59
102	Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). *Cancer Science*, **2011**, 102, 1761-8	6.9	22
101	Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. *Structure*, **2011**, 19, 1274-82	5.2	75
100	Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. *Journal of Immunological Methods*, **2011**, 373, 67-78	2.5	38
99	Anti-galactose-α1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. *Nature Biotechnology*, **2011**, 29, 574-6	44.5	92
98	Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. *Journal of Immunology*, **2011**, 187, 3383-90	5.3	38
97	Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers. *European Journal of Immunology*, **2011**, 41, 2436-46	6.1	30
96	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. *Haematologica*, **2011**, 96, 284-90	6.6	172
95	Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *Journal of Immunology*, **2011**, 186, 1840-8	5.3	649
94	Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. *Journal of Immunology*, **2011**, 187, 3238-46	5.3	97
93	Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. *Journal of Immunology*, **2011**, 187, 3438-47	5.3	86
92	Reply to Fab-arm exchange. *Nature Biotechnology*, **2010**, 28, 125-126	44.5	

91	In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. *Cancer Research*, **2010**, 70, 3209-17	10.1	112
90	Late B cell depletion with a human anti-human CD20 IgG1 monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets. *Journal of Immunology*, **2010**, 185, 3990-4003	5.3	49
89	Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. *Journal of Immunology*, **2010**, 184, 512-20	5.3	183
88	HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. *Haematologica*, **2010**, 95, 2063-71	6.6	24
87	High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging. *Journal of Immunological Methods*, **2010**, 352, 140-6	2.5	9
86	Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system. *Biotechnology and Bioengineering*, **2010**, 105, 350-7	4.9	39
85	Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. *Journal of Immunology*, **2009**, 183, 749-58	5.3	200
84	Immunology. Two-in-one designer antibodies. *Science*, **2009**, 323, 1567-8	33.3	9
83	N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. *Biotechnology Progress*, **2009**, 25, 244-51	2.8	72
82	Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. *Nature Biotechnology*, **2009**, 27, 767-71	44.5	228
81	Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. *Nature Medicine*, **2009**, 15, 951-4	50.5	449
80	Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.. *Blood*, **2009**, 114, 1725-1725	2.2	9
79	Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. *British Journal of Haematology*, **2008**, 140, 303-12	4.5	77
78	The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 6109-14	11.5	47
77	IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. *Journal of Immunology*, **2008**, 181, 669-79	5.3	121
76	Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. *Journal of Immunology*, **2008**, 181, 822-32	5.3	105
75	Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. *Cancer Research*, **2008**, 68, 4998-5003	10.1	129
74	Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. *Journal of Immunology*, **2008**, 180, 4338-45	5.3	20

73	Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. *PLoS Medicine*, **2008**, 5, e64	11.6	96
72	Genetic vaccination: one-shot shopping for immediate and sustained protection. *Molecular Therapy*, **2008**, 16, 6-7	11.7	
71	Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. *Blood*, **2008**, 112, 2390-9	2.2	169
70	Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. *Blood*, **2008**, 112, 4354-5; author reply 4355-6	2.2	5
69	Novel human antibody therapeutics: the age of the Umabs. *Biotechnology Journal*, **2008**, 3, 1157-71	5.6	38
68	Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. *Annals of the New York Academy of Sciences*, **2008**, 1132, 174-9	6.5	18
67	Fc receptor but not complement binding is important in antibody protection against HIV. *Nature*, **2007**, 449, 101-4	50.4	708
66	Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. *PLoS Pathogens*, **2007**, 3, e9	7.6	187
65	A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. *Cancer Research*, **2007**, 67, 9945-53	10.1	49
64	Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. *Journal of Molecular Biology*, **2007**, 369, 696-709	6.5	63
63	Immunogenicity screening in protein drug development. *Expert Opinion on Biological Therapy*, **2007**, 7, 405-18	5.4	70
62	Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. *Science*, **2007**, 317, 1554-7	33.3	693
61	Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. *Infection and Immunity*, **2006**, 74, 362-9	3.7	37
60	Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. *Cancer Research*, **2006**, 66, 7630-8	10.1	110
59	The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. *Journal of Immunology*, **2006**, 177, 362-71	5.3	496
58	Therapeutic antibody gene transfer: an active approach to passive immunity. *Molecular Therapy*, **2004**, 10, 411-6	11.7	27
57	The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. *Journal of Virology*, **2004**, 78, 3155-61	6.6	102
56	Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. *Journal of Immunology*, **2004**, 173, 4699-707	5.3	129

55	Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. *Blood*, **2004**, 104, 1793-800	2.2	505
54	A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. *Journal of Virology*, **2003**, 77, 6965-78	6.6	66
53	Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. *Journal of Virology*, **2003**, 77, 5863-76	6.6	90
52	Characterization of a fully human IgG1 reconstructed from an anti-AChR Fab. *Annals of the New York Academy of Sciences*, **2003**, 998, 399-400	6.5	2
51	Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history?. *Trends in Immunology*, **2003**, 24, 467-9	14.4	9
50	Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design. *Advances in Experimental Medicine and Biology*, **2003**, 535, 55-66	3.6	32
49	Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. *Journal of Virology*, **2003**, 77, 642-58	6.6	225
48	Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. *Journal of Virology*, **2003**, 77, 9993-10003	6.6	104
47	Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. *Journal of Virology*, **2003**, 77, 353-65	6.6	165
46	Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. *Journal of Clinical Investigation*, **2003**, 112, 1571-1580	15.9	131
45	Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. *Journal of Virology*, **2002**, 76, 7760-76	6.6	146
44	Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6913-8	11.5	190
43	Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. *Journal of Virology*, **2002**, 76, 6408-12	6.6	170
42	Contrasting IgG structures reveal extreme asymmetry and flexibility. *Journal of Molecular Biology*, **2002**, 319, 9-18	6.5	209
41	Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. *Acta Crystallographica Section D: Biological Crystallography*, **2001**, 57, 168-71		37
40	Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. *Journal of Virology*, **2001**, 75, 6692-9	6.6	83
39	Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. *Journal of Virology*, **2001**, 75, 12198-208	6.6	141
38	Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. *Science*, **2001**, 293, 1155-9	33.3	764

37	Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. *Journal of Virology*, **2001**, 75, 5721-9	6.6	102
36	Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. *Journal of Virology*, **2001**, 75, 12161-8	6.6	204
35	Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. *Journal of Virology*, **2001**, 75, 10892-905	6.6	680
34	The antiviral activity of antibodies in vitro and in vivo. *Advances in Immunology*, **2001**, 77, 195-262	5.6	203
33	gp120: Biologic aspects of structural features. *Annual Review of Immunology*, **2001**, 19, 253-74	34.7	215
32	Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. *Journal of Virology*, **2001**, 75, 8340-7	6.6	591
31	Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. *Aids*, **2000**, 14, 1117-22	3.5	80
30	Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?. *Nature Medicine*, **2000**, 6, 123-5	50.5	56
29	Antibody and virus: binding and neutralization. *Virology*, **2000**, 270, 1-3	3.6	80
28	In vitro characterization of five humanized OKT3 effector function variant antibodies. *Cellular Immunology*, **2000**, 200, 16-26	4.4	171
27	Antibodies in human infectious disease. *Immunologic Research*, **2000**, 21, 265-78	4.3	11
26	The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. *Journal of Immunology*, **2000**, 164, 5313-8	5.3	103
25	Mechanisms and in-vivo Significance of HIV-1 Neutralisation **2000**, 99-132		
24	Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. *Immunity*, **1999**, 10, 431-8	32.3	198
23	Ebola virus can be effectively neutralized by antibody produced in natural human infection. *Journal of Virology*, **1999**, 73, 6024-30	6.6	234
22	Ebola Virus, Neutrophils, and Antibody Specificity **1998**, 282, 843a-843		26
21	Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. *Journal of Virology*, **1998**, 72, 585-92	6.6	34
20	Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. *Journal of Virology*, **1998**, 72, 10270-4	6.6	63

19	Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. *Journal of Virology*, **1998**, 72, 9788-94	6.6	75
18	Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. *Journal of Virology*, **1998**, 72, 3512-9	6.6	168
17	Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. *Journal of Virology*, **1998**, 72, 6332-8	6.6	119
16	Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. *Journal of Experimental Medicine*, **1997**, 186, 1287-98	16.6	108
15	Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. *Journal of Molecular Biology*, **1997**, 267, 684-95	6.5	51
14	HIV-1 antibody--debris or virion?. *Nature Medicine*, **1997**, 3, 366-7	50.5	137
13	Importance of anti-HIV-1 antibodies. *Nature Medicine*, **1997**, 3, 591-591	50.5	1
12	Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. *Nature Medicine*, **1997**, 3, 1389-93	50.5	246
11	Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. *Immunology Letters*, **1997**, 57, 105-12	4.1	51
10	Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design". *Immunology Letters*, **1997**, 58, 125-32	4.1	23
9	Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towards antiviral immunotherapy. *Chemical Immunology and Allergy*, **1997**, 65, 18-56		22
8	Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. *AIDS Research and Human Retroviruses*, **1996**, 12, 911-24	1.6	70
7	Mouse/human chimeric IgE antibodies directed to the house dust mite allergen Der p 2. *International Archives of Allergy and Immunology*, **1995**, 107, 465-6	3.7	11
6	Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. *Aids*, **1995**, 9, F1-6	3.5	115
5	Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation. *European Journal of Immunology*, **1994**, 24, 1956-60	6.1	31
4	Interaction of a human Fc gamma RIIb1 (CD32) isoform with murine and human IgG subclasses. *International Immunology*, **1993**, 5, 239-47	4.9	48
3	Polymorphism of the human Fc gamma receptor II (CD32): molecular basis and functional aspects. *Immunobiology*, **1992**, 185, 175-82	3.4	26
2	Preparation of genetically engineered monoclonal antibodies for human immunotherapy. *Human Antibodies*, **1992**, 3, 137-145	1.3	7

1	Functional characterization of a novel anti-B7 monoclonal antibody. *European Journal of Immunology*, **1992**, 22, 3071-5	6.1	51